F M Investments LLC bought a new position in Biohaven Ltd. (NYSE:BHVN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 26,338 shares of the company's stock, valued at approximately $984,000.
Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Biohaven by 8.1% during the fourth quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock worth $314,267,000 after acquiring an additional 628,211 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Biohaven by 144.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock valued at $73,922,000 after purchasing an additional 1,169,721 shares during the period. Geode Capital Management LLC boosted its stake in Biohaven by 11.1% during the 4th quarter. Geode Capital Management LLC now owns 1,905,366 shares of the company's stock valued at $71,182,000 after purchasing an additional 190,754 shares during the period. ARS Investment Partners LLC grew its position in Biohaven by 1.0% in the 4th quarter. ARS Investment Partners LLC now owns 1,040,712 shares of the company's stock worth $38,871,000 after purchasing an additional 10,473 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Biohaven in the fourth quarter valued at approximately $33,711,000. 88.78% of the stock is owned by institutional investors and hedge funds.
Biohaven Trading Up 0.3 %
Shares of NYSE BHVN traded up $0.05 during mid-day trading on Tuesday, reaching $18.56. The company had a trading volume of 1,127,581 shares, compared to its average volume of 1,118,164. Biohaven Ltd. has a 1-year low of $15.79 and a 1-year high of $55.70. The stock has a market cap of $1.89 billion, a PE ratio of -1.99 and a beta of 1.33. The company has a 50-day moving average price of $29.63 and a two-hundred day moving average price of $39.12.
Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, research analysts expect that Biohaven Ltd. will post -8.9 EPS for the current year.
Insider Activity at Biohaven
In other Biohaven news, Director John W. Childs purchased 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the acquisition, the director now owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. This represents a 1.43 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 16.00% of the stock is owned by insiders.
Wall Street Analyst Weigh In
BHVN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. decreased their price objective on Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Cantor Fitzgerald restated an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on shares of Biohaven and gave the company a "buy" rating in a research report on Thursday, March 20th. Royal Bank of Canada restated an "outperform" rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Finally, HC Wainwright reiterated a "buy" rating and set a $54.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th. Fourteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Biohaven currently has an average rating of "Buy" and an average price target of $62.77.
Check Out Our Latest Stock Analysis on BHVN
Biohaven Company Profile
(
Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Featured Articles
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
